



Kilitch Drugs (India) Ltd.

9<sup>th</sup> November, 2023

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Outcome of Board Meeting**

Dear Sir,

In continuation of our letter dated 1<sup>st</sup> November, 2023 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, 9<sup>th</sup> November, 2023 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30<sup>th</sup> September, 2023. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference.

The Board Meeting commenced at 16:30 hours and concluded at ~~18:40~~ hours.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
Managing Director



**KILITCH DRUGS (INDIA) LIMITED**

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2023**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com


CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	Three Months Ended			Six Months Ended		Year Ended
		30/09/2023	30/06/2023	30/09/2022	30/09/2023	30/09/2022	31/03/2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Income</b>						
	Net Sales/ Income from operations	3,157.37	3,112.48	2,242.85	6,269.85	4,599.73	11,778.35
	Other Income	91.89	97.83	66.07	189.72	205.28	459.76
	<b>Total Income</b>	<b>3,249.26</b>	<b>3,210.31</b>	<b>2,308.92</b>	<b>6,459.57</b>	<b>4,805.01</b>	<b>12,238.11</b>
<b>2</b>	<b>Expenses</b>						
	Cost of Materials Consumed	1,534.19	1,367.36	969.13	2,901.55	2,128.00	5,826.62
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(35.39)	30.32	(18.07)	(5.07)	22.04	22.68
	Employee Benefit Expenses	200.33	196.83	180.08	397.16	338.84	746.64
	Finance Cost	42.48	37.87	22.85	80.35	30.13	98.53
	Depreciation and Amortisation Expenses	27.86	25.68	31.34	53.54	58.57	133.71
	Export Product Registration/Commission	268.46	266.63	204.73	535.09	373.02	1,130.42
	Other Expenses	617.95	727.50	592.67	1,345.45	1,110.75	2,334.65
	<b>Total Expenses</b>	<b>2,655.88</b>	<b>2,652.19</b>	<b>1,982.73</b>	<b>5,308.07</b>	<b>4,061.35</b>	<b>10,293.25</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional items (1-2)</b>	<b>593.38</b>	<b>558.12</b>	<b>326.19</b>	<b>1,151.50</b>	<b>743.66</b>	<b>1,944.86</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	<b>593.38</b>	<b>558.12</b>	<b>326.19</b>	<b>1,151.50</b>	<b>743.66</b>	<b>1,944.86</b>
<b>6</b>	Less: Tax Expenses:-						
	Current Tax	176.30	198.55	(56.74)	374.85	71.26	419.76
	Deferred Tax	(7.27)	(59.31)	18.44	(66.58)	6.46	(46.63)
<b>7</b>	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	<b>424.35</b>	<b>418.88</b>	<b>364.49</b>	<b>843.23</b>	<b>665.94</b>	<b>1,571.73</b>
<b>8</b>	Other Comprehensive Income (after tax)	122.26	220.61	142.64	342.87	(77.50)	(31.75)
<b>9</b>	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>546.61</b>	<b>639.49</b>	<b>507.13</b>	<b>1,186.10</b>	<b>588.44</b>	<b>1,539.98</b>
<b>10</b>	Paid-Up equity share capital (Face Value Rs 10 per share)	<b>1,608.23</b>	<b>1,558.23</b>	<b>1,558.23</b>	<b>1,608.23</b>	<b>1,558.23</b>	<b>1,558.23</b>
<b>11</b>	Other Equity						<b>18,034.86</b>
<b>12</b>	<b>Earning per share (not annualised)</b>						
	(a) Basic	2.60	2.69	2.34	5.29	4.27	10.09
	(b) Diluted	2.60	2.69	2.34	5.29	4.27	10.09

**Notes:**


- The above Unaudited Financial Results of the Company for the quarter and six months ended 30th September, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9th November, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- During the quarter, 5,00,000 Equity Share warrants, which were issued to the promoters of the company on a preferential basis in January, 2022, at the issue price of Rs. 177.15 per warrant, have been converted into 5,00,000 Equity Shares of Rs. 10/- each at a premium of Rs. 167.15 per share.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.



Place : Mumbai  
Dated: 9th November, 2023



For and on behalf of the Board of Directors



**Mukund Mehta**  
Managing Director  
DIN: 00147876

**KILITCH DRUGS (INDIA) LIMITED**

UNAUDITED STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER 2023

(Rs. in Lakhs)

Particulars	As at 30th September, 2023	As at 31st March, 2023
	Unaudited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
- Property, Plant and Equipment	1,474.25	1,481.61
- Capital work-in-progress	186.01	131.15
- Other Intangible Assets	25.79	26.32
<b>Financial assets</b>		
- Investments	7,127.76	7,109.75
- Loans/Advances	4,947.01	4,817.14
- Other Financial Assets	3.11	1.79
Deferred tax assets (Net)	263.96	197.38
(A)	<b>14,027.89</b>	<b>13,765.14</b>
<b>Current Assets</b>		
- Inventories	254.68	204.46
<b>Financial assets</b>		
- Investments	4,273.45	3,919.68
- Trade Receivables	6,564.68	5,310.22
- Cash & Cash Equivalents	579.21	1,783.58
- Other Bank Balances	71.36	13.39
- Other Financial Assets	1.33	2.15
Other Current Assets	1,170.37	243.17
(B)	<b>12,915.08</b>	<b>11,476.65</b>
<b>TOTAL ASSETS (A + B)</b>	<b>26,942.97</b>	<b>25,241.79</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
- Equity Share Capital	1,608.23	1,558.23
- Other Equity	19,556.71	18,034.86
(A)	<b>21,164.94</b>	<b>19,593.09</b>
<b>Liabilities</b>		
<b>Non-Current liabilities</b>		
- Provisions	6.83	6.83
(B)	<b>6.83</b>	<b>6.83</b>
<b>Current liabilities</b>		
<b>Financial Liabilities</b>		
- Borrowings	2,840.47	2,186.42
- Trade Payables		
Micro and Small Enterprises	-	-
Others	2,299.35	2,883.64
- Other Financial Liabilities	3.94	3.87
Provisions	154.68	151.27
Current Tax Liabilities [Net]	463.20	403.89
Other Current Liabilities	9.56	12.78
(C)	<b>5,771.20</b>	<b>5,641.87</b>
<b>TOTAL EQUITY AND LIABILITIES (A+B+C)</b>	<b>26,942.97</b>	<b>25,241.79</b>

For and on behalf of the Board of Directors

*(Signature)*



*(Signature)*

**Mukund Mehta**  
Managing Director  
DIN: 00147876



Place : Mumbai

Dated: 9th November, 2023

**KILITCH DRUGS (INDIA) LIMITED**  
**UNAUDITED STANDALONE CASH FLOW STATEMENT FOR SIX MONTHS ENDED 30TH SEPTEMBER, 2023**

(Rs. in Lakhs)

Particulars	Six Months Ended 30th September, 2023		Six Months Ended 30th September, 2022	
	Unaudited		Unaudited	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		1,151.50		743.66
<i>Adjustments for:</i>				
Depreciation and amortization	53.54		58.57	
Interest income	(110.89)		(107.71)	
Dividend income	(0.79)		(0.79)	
(Profit)/Loss on sale of Investments	4.42		(75.99)	
Sundry Balances written back	(0.08)		(2.25)	
Provision for Gratuity & Leave Encashment	4.78		6.00	
Interest Expenses	80.35		30.13	
Bad Debts / Provision for Doubtful Debts	271.36		12.10	
Net unrealised exchange (gain) / loss	24.09		43.44	(36.48)
<b>Operating profit / (loss) before working capital changes</b>		<b>1,478.29</b>		<b>707.18</b>
<i>Changes in working capital:</i>				
<i>Operating Assets:</i>				
Inventories	(50.22)		130.52	
Trade receivables	(1,549.92)		189.57	
Other current assets	(927.20)		(20.44)	
Deposits & advances	3.39		(20.04)	
Other financial assets	0.82		1.07	
<i>Operating Liabilities:</i>				
Trade payables	(584.21)		(556.48)	
Other current liabilities	(3.15)		(37.56)	
Provisions	(1.37)	(3,111.86)	30.40	(282.97)
<b>Gross cash flow from / (used in) operating activities</b>		<b>(1,633.57)</b>		<b>424.21</b>
Direct Taxes (Paid) /refunded		(436.02)		(215.54)
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>(2,069.59)</b>		<b>208.67</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchases of Property, Plant & Equipment and CWIP	(100.50)		(187.96)	
Loans/Advances to related Parties	(133.26)		(1,120.25)	
Proceeds/(Purchases) (Net) of Current Investments	105.13		733.96	
Proceeds/(Purchases) (Net) of Non-Current Investments	(18.00)		137.46	
Movement in other Bank balances	(59.28)		84.47	
Interest received	110.89		107.71	
Dividend received	0.79		0.79	
		(94.23)		(243.83)
		(94.23)		(243.83)
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(94.23)</b>		<b>(243.83)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Application money received against Share Warrants	-		250.00	
Equity Share Capital issued - incl. Premium (Net of conversion of Appl. Money on warrants received)	385.75		-	
Proceeds from Borrowings (Net of Repayments)	654.05		(149.44)	
Interest paid	(80.35)		(30.13)	
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>959.45</b>		<b>70.43</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(1,204.37)</b>		<b>35.27</b>
Cash and cash equivalents at the beginning		1,783.58		244.96
<b>Cash and cash equivalents at the end</b>		<b>579.21</b>		<b>280.23</b>
<b>Cash and cash equivalents at the end *</b>				
* Comprises:				
(a) Cash on hand		1.73		2.42
(b) Balances with banks				
(i) In current accounts		573.62		273.93
(ii) In earmarked accounts		3.86		3.88
		<b>579.21</b>		<b>280.23</b>

Place : Mumbai  
Dated: 9th November, 2023



**Mukund Mehta**  
Managing Director  
DIN: 00147876





**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of**  
**Kilitch Drugs (India) Limited**


1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and half year ended 30th September, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
  2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
  3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
  4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with
-

---

relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For SuryaPrakash Maurya & Company  
Chartered Accountants**

Firm Registration No.: 147410W



**SuryaPrakash Maurya**

Proprietor

Membership No.: 178258

ICAI UDIN: 23178258BGGVD7416



Place: Mumbai

Date: 09/11/2023

---

**KILITCH DRUGS (INDIA) LIMITED**  
**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2023**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)


Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended			Six Months Ended		Year Ended
		30/09/2023	30/06/2023	30/09/2022	30/09/2023	30/09/2022	31/03/2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b><u>Income</u></b>						
	Net Sales/Income from Operations	4,120.22	3,655.70	3,069.70	7,775.92	6,414.97	13,959.90
	Other Income	48.91	56.25	23.96	105.16	121.10	291.80
	<b>Total Income</b>	<b>4,169.13</b>	<b>3,711.95</b>	<b>3,093.66</b>	<b>7,881.08</b>	<b>6,536.07</b>	<b>14,251.70</b>
<b>2</b>	<b><u>Expenses</u></b>						
	Cost of Materials Consumed	2,055.95	1,670.81	1,558.36	3,726.77	3,534.50	7,453.23
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(35.40)	30.32	(18.07)	(5.07)	22.04	22.67
	Employee Benefit Expenses	261.15	252.34	307.59	513.49	586.54	1,173.36
	Finance Cost	150.89	149.94	175.19	300.84	242.34	491.89
	Depreciation and Amortisation Expenses	81.66	78.91	88.66	160.57	170.93	355.06
	Export Product Registration/Commission	268.49	268.86	207.64	537.35	380.80	1,142.40
	Other expenses	708.08	815.54	618.91	1,523.62	1,153.82	2,411.66
	<b>Total Expenses</b>	<b>3,490.82</b>	<b>3,266.72</b>	<b>2,938.28</b>	<b>6,757.57</b>	<b>6,090.97</b>	<b>13,050.27</b>
<b>3</b>	<b>Profit before Exceptional items (1-2)</b>	<b>678.31</b>	<b>445.23</b>	<b>155.38</b>	<b>1,123.51</b>	<b>445.10</b>	<b>1,201.43</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit from ordinary activities before tax (3+4)</b>	<b>678.31</b>	<b>445.23</b>	<b>155.38</b>	<b>1,123.51</b>	<b>445.10</b>	<b>1,201.43</b>
<b>6</b>	Less : Tax Expenses						
	Current Income Tax	176.30	198.55	(56.74)	374.85	71.26	419.76
	Deferred Tax	(7.35)	(59.27)	18.47	(66.63)	6.49	(46.60)
<b>7</b>	<b>Profit after tax for the period from continuing operations (5-6)</b>	<b>509.36</b>	<b>305.95</b>	<b>193.65</b>	<b>815.29</b>	<b>367.35</b>	<b>828.27</b>
	Add/(Less): Share in Profits /(Loss) of Associates	-	-	-	-	-	-
<b>8</b>	<b>Net Profit/(Loss) After Tax &amp; Share in Profits /(Loss) of Associates</b>	<b>509.36</b>	<b>305.95</b>	<b>193.65</b>	<b>815.29</b>	<b>367.35</b>	<b>828.27</b>
<b>9</b>	<b>Other Comprehensive Income (after Tax)</b>	<b>122.25</b>	<b>220.61</b>	<b>142.64</b>	<b>342.86</b>	<b>(77.50)</b>	<b>(31.75)</b>
<b>10</b>	<b>Total Comprehensive Income (after taxes) (8+9)</b>	<b>631.61</b>	<b>526.56</b>	<b>336.29</b>	<b>1,158.15</b>	<b>289.85</b>	<b>796.52</b>




<b>11</b>	<b>Net Profit / (Loss) attributable to</b>						
	a) Owner of the Company	474.10	335.71	242.78	809.79	451.40	1,044.81
	b) Non Controlling interest	35.26	(29.76)	(49.13)	5.50	(84.04)	(216.54)
<b>12</b>	<b>Other Comprehensive Income attributable to</b>						
	a) Owner of the Company	122.25	220.61	142.64	342.86	(77.50)	(31.75)
	b) Non Controlling interest	-	-	-	-	-	-
<b>13</b>	<b>Total Income attributable to</b>						
	a) Owner of the Company	596.35	556.32	385.42	1,152.65	373.90	1,013.06
	b) Non Controlling interest	35.26	(29.76)	(49.13)	5.50	(84.05)	(216.54)
<b>14</b>	<b>Paid-Up equity share capital (Face Value Rs. 10 per share)</b>	<b>1,608.23</b>	<b>1,558.23</b>	<b>1,558.23</b>	<b>1,608.23</b>	<b>1,558.23</b>	<b>1,558.23</b>
<b>15</b>	<b>Other Equity</b>						<b>13,601.49</b>
<b>16</b>	<b>Earning per share (not annualised)</b>						
	(a) Basic	2.93	2.15	1.56	5.08	2.90	6.71
	(b) Diluted	2.93	2.15	1.56	5.08	2.90	6.71

**Notes:**

- The above Unaudited Consolidated Financial Results of the Company for the quarter and six months ended 30th September, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 9th November, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- During the quarter, 5,00,000 Equity Share warrants, which were issued to the promoters of the company on a preferential basis in January, 2022, at the issue price of Rs. 177.15 per warrant, have been converted into 5,00,000 Equity Shares of Rs. 10/- each at a premium of Rs. 167.15 per share.
- The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.




Place: Mumbai  
Date: 9th November, 2023

**For and on behalf of the Board of Directors**



**Mukund P. Mehta**  
Director  
DIN: 00147876





<b>KILITCH DRUGS (INDIA) LIMITED</b>		
UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30TH SEPTEMBER, 2023		
CIN:L24239MH1992PLC066718		
(Rs. In Lakhs)		
Particulars	As at 30th September, 2023	As at 31st March, 2023
	Unaudited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and Equipment	4,367.56	4,373.89
Capital work-in-progress	342.91	361.92
Other Intangible assets	2,005.77	2,048.43
<b>Financial assets</b>		
- Investments	2,283.97	2,265.96
- Loans/Advances	58.67	62.06
- Other Financials Assets	3.11	1.79
Deferred tax assets (Net)	264.40	197.77
<b>(A)</b>	<b>9,326.39</b>	<b>9,311.82</b>
<b>Current assets</b>		
Inventories	254.68	204.46
<b>Financial assets</b>		
- Investments	4,273.45	3,919.68
- Trade and other receivables	6,640.11	5,428.70
- Cash and cash equivalents	865.31	1,984.60
- Other Bank Balances	71.36	13.39
- Other Financials Assets	1.33	2.15
Other current assets	2,267.85	1,087.33
<b>(B)</b>	<b>14,374.09</b>	<b>12,640.31</b>
<b>TOTAL ASSETS (A + B)</b>	<b>23,700.48</b>	<b>21,952.13</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share capital	1,608.23	1,558.23
Other Equity	15,133.89	13,601.49
<b>Equity attributable to the owners</b>	<b>16,742.12</b>	<b>15,159.72</b>
Non-controlling interest	(74.56)	(101.73)
<b>(A)</b>	<b>16,667.56</b>	<b>15,057.99</b>
<b>Liabilities</b>		
<b>Non - Current Liabilities</b>		
Provisions	6.83	6.83
<b>(B)</b>	<b>6.83</b>	<b>6.83</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
- Borrowings	2,873.40	2,219.35
- Trade Payables		
Micro and Small Enterprises	-	-
Others	3,511.86	4,087.45
- Other financial liabilities	3.94	3.87
Provisions	155.04	151.63
Current tax Liabilities (Net)	463.20	403.89
Other current liabilities	18.65	21.12
<b>(C)</b>	<b>7,026.09</b>	<b>6,887.31</b>
<b>TOTAL EQUITY AND LIABILITIES (A + B)</b>	<b>23,700.48</b>	<b>21,952.13</b>

For and on behalf of the Board of Directors

*Amritya*



Place : Mumbai  
Date : 9th November, 2023

*Mukund P. Mehta*

**Mukund P. Mehta**  
Managing Director  
DIN: 00147876



**KILITCH DRUGS (INDIA) LIMITED**  
**UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE SIX MONTHS ENDED ON 30TH SEPTEMBER, 2023**  
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs)

Particulars	Six Months ended 30th September, 2023		Six Months ended 30th September, 2022	
	Unaudited		Unaudited	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		1,123.52		445.10
Adjustments for:				
Depreciation and amortisation	160.57		170.93	
Interest income	(25.39)		(23.53)	
Dividend income	(0.79)		(0.79)	
(Profit)/Loss on sale of Investments	4.42		(75.99)	
Sundry Balances written back	(0.08)		(2.25)	
Provision for Gratuity & Leave Encashment	4.78		6.00	
Interest Expenses	300.84		242.34	
Bad Debts / Provision for Doubtful Debts	271.36		12.10	
Net unrealised exchange (gain) / loss	24.09	739.81	43.48	372.29
<b>Operating profit / (loss) before working capital changes</b>		1,863.33		817.39
Changes in working capital:				
Operating Assets:				
Inventories	(50.22)		130.52	
Trade receivables	(1,506.86)		65.92	
Other financial Assets	0.82		1.07	
Other current assets	(1,180.53)		475.70	
Deposit & Advances	3.39		-	
Operating Liabilities:				
Trade payables	(575.51)		(247.28)	
Other financial liabilities	0.07		-	
Other current liabilities	(2.47)		(36.76)	
Short-term provisions	(1.37)	(3,312.68)	30.76	419.93
Gross cash flow from / (used in) operating activities		(1,449.35)		1,237.32
Direct Taxes (Paid) / refunded		(436.02)		(215.53)
<b>Net cash flow from / (used in) operating activities</b>		<b>(1,885.37)</b>		<b>1,021.79</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on PPE,CWIP including capital advances	(48.58)		(453.82)	
Proceeds (Net) from the sale of Current investments	105.13		733.96	
(Purchase)/Sale (Net) of long-term investments:	(18.00)		137.46	
Loans/ Advances Related Party	-		(1,056.75)	
Movement in other Bank balance	(59.28)		84.47	
Interest received	25.39		24.60	
Dividend received	0.79		0.79	
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>5.45</b>		<b>(529.29)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Equity Share Capital issued incl. premium				
(Net of conversion of Appl. Money on Warrants received)	385.75		-	
Application money received against Share Warrants	-		250.00	
Proceeds from Borrowings (Net of Repayments)	654.05		(149.44)	
Proceeds from Minorities	21.67		(28.65)	
Interest paid	(300.84)		(242.34)	
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>760.63</b>		<b>(170.43)</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(1,119.29)</b>		<b>322.07</b>
Cash and cash equivalents at the beginning		1,984.60		1,006.15
<b>Cash and cash equivalents at the end</b>		<b>865.31</b>		<b>1,328.22</b>
<b>Cash and cash equivalents at the end *</b>				
* Comprises:				
(a) Cash on hand		1.86		2.45
(b) Balances with banks				
(i) In current accounts		859.59		1,321.89
(ii) In earmarked accounts		3.86		3.88
		<b>865.31</b>		<b>1,328.22</b>

*[Signature]*



For and on behalf of the Board of Directors

*[Signature]*

**Mukund P. Mehta**  
 Managing Director  
 DIN: 00147876

Place : Mumbai  
 Date : 9th November, 2023



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of  
Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2023 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation

---

---

33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

**List of Subsidiaries:**

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary

5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total assets of Rs. 1,983.64 Lakhs, total revenues of Rs. Nil and Rs. Nil, total net profit/(loss) after tax of Rs. (21.84) Lakhs and Rs. (44.61) Lakhs and total comprehensive income/(loss) of Rs. (21.84) Lakhs and Rs. (44.61) Lakhs for the quarter ended 30th September, 2023 and for the period from 1st April, 2022 to 30th September, 2023, respectively and net cash inflow of Rs. 0.10 Lakhs for the period from 1st April, 2023 to 30th September, 2023. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

(b)The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects ,total assets of Rs. 6,060.12 Lakhs, total revenues of Rs. 962.86 Lakhs and Rs. 1,509.20 Lakhs, total net profit/(loss) after tax of Rs.106.84 Lakhs and Rs. 16.67 Lakhs and total comprehensive income/(loss) of Rs. 106.84 Lakhs and Rs. 16.67 Lakhs for the quarter ended 30th September, 2023 and for the period from 1st April, 2023 to 30th September, 2023, respectively and net cash inflow of Rs. 84.98 Lakhs for the period from 1st April, 2023 to 30th September, 2023 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.


6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
-

---

**For SuryaPrakash Maurya & Company**

**Chartered Accountants**

Firm Registration No.: 147410W



**SuryaPrakash Maurya**

Proprietor

Membership No.: 178258

ICAI UDIN: 23178258BGVGVE2300



Place: Mumbai

Date: 09/11/2023

